Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: – Merck looks to fill Keytruda’s shoes; Novartis aims to push through largest expiry period; Novo warns of steep sales decline; Pfizer bullish on obesity; and Lilly expects orforglipron success.
Scrip - February 9, 2026

Bundling Approach Brings $382M Antitrust Verdict Against Medtronic
The medtech giant violated USA and California antitrust law in its sales practices for devices used to cut and seal blood vessels during surgery, a jury found. Rival firm Applied Medical brought the case.
Medtech Insight - February 6, 2026

Global Medtech Guidance Tracker: January 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - February 6, 2026

Boston Scientific Says Penumbra Deal Could Lift Market Growth Profile As 10%+ Organic Target Holds
Boston Scientific also announced a new collaboration with Siemens Healthineers aimed at expanding its structural heart imaging capabilities. The companies plan to develop and commercialize a next-generation 4D intracardiac echocardiography catheter, ACUNAV.
Medtech Insight - February 6, 2026

Boston Scientific Sees EP Growth Exceeding Market Despite PFA Competition
Boston Scientific exits 2025 with roughly a 65% share of the PFA market, within a segment the company believes will grow about 15%.
Medtech Insight - February 6, 2026

Abbott Says Plans To Launch Dual Diabetes Sensor Unimpeded By Latest Warning Letter
A warning letter from the US FDA citing concerns of some Abbott continuous glucose monitors will not stop the company from launching a novel diabetes sensor later this year as planned.
Medtech Insight - February 6, 2026

Industry View: Good Year Shaping For Regulatory Progress In The UK – And EU
With EU MDR/IVDR review proposals out, UK MHRA progress on a premarket regulation and, up ahead, a prospective consultation on accepting the CE marking indefinitely, now is a good time to assess EU-UK regulatory positions for the benefit of UK industry, says ABHI director Steve Lee.
Medtech Insight - February 6, 2026

Real Estate Is Wellness Economy Home For Driving Growth As Nutrition Remains Largest Sector
“Wellness real estate has been the leading contributor to wellness economy growth globally, as well as among many high-growth countries that also fall into the top 25 largest markets,” GWI reports.
HBW Insight - February 8, 2026

More America First Fees: US FDA Proposes GDUFA Facility Fee Waiver For Domestic Construction
The FDA wants to waive facility fees for three years if a sponsor breaks ground on a US-based manufacturing plant, but industry is concerned the idea will force other sponsors to subsidize competition.
Generics Bulletin - February 6, 2026

Sandoz Enters Canadian Ophthalmology Market With Eylea Biosimilar
Sandoz’s aflibercept biosimilar Enzeevu launch in Canada comes just a few days after the firm signed a multiple asset deal, including an undisclosed ophthalmology product, with Alvotech, which recently gained immediate launch for its Eylea rival in the country.
Generics Bulletin - February 6, 2026

‘Access Is A Right, Not A Privilege’ – Medicines For Europe’s Saltofte Sets Out Priorities
After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.
Generics Bulletin - February 6, 2026

Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Generics Bulletin - February 6, 2026

Update On ADCs: Sales, Deals, Targets And Approvals
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.  
In Vivo - February 5, 2026